Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I will revisit KATX board again.
I was just looking this morning at the ibox and only saw the OS information as of 1/2010. I was not able to see the historical information right off but will check again. I am trying to find out how they are handling their stock volume over time and where the value of this is in 1 to 3, to even 6 months.
Thanks
KATX (.06) Do you have company information on them?
I have tried to do research on this company within my two brokerage companies and I am not able to look up any information on them.
Do you have a projected target price on this company in the next month, 3 months?
Do you know the Outstanding Shares for this company over the last 5 years? I am trying to determine if thay have did a reverse stock split or if they may be deluting their shares by adding more each year as some other companies have done.
Or maybe you have a link to a website that will give all the technical information on them that I am not able to find in my brokerage companies.
Thank you for your time and help.
RNN, wondering how today will play out with the news today.
Will this be a selling into the news, or a run up for what is coming?
RNN, I would tend to agree with you on that.
RNN (3.75) Up in AH.
A high of 3.83 so far.
If this should be going over $4 tomorrow and on it way to $5 then I would not be surprised that we closer much higher in AH.
RNN thought from Rexahn Pharmaceuticals board. ($5?)
Some on the RNN board here feels this stock could be going up to $5. Will be interesting to see what happens tomorrow.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48873559
Yes, click on "Show iBox" to open it up.
AVNR... Anyone see $0.1342 trades occuring?
I am seeing trades on my level 2 that is showing executions at around $0.1342. Anyone else noticing them on their screen? Seeing them around 13:04/13:05.
10,000 shares just executed just before 13:07.
I am wondering if these are true executions that they deal with insider buying occurring. That or my Level II is messed up.
Here is a screen shot of my Level II
VASO, In at .27
RPC, In at .6915
POZN Pullback Thought.
I think POZN has been doing extremely well and seems to have good following.
What concerns me is that there has not really been any correction to this stock price since mid-March as you can see in the chart attached, plus it appears to me we have several gaps in where it jumps almost a dollar each time.
I wish I could give you a good answer on what will or may happen. It has had a wonderful run up here this past two+ weeks with no real correction. It also seems that the daily volume is high on days the price rises up and more flat when it does not, which I think is a good thing to see.
I also wish I could see how any shorting may be happening each day, but I do not have the tools I feel to actually tell. If anyone has that tool information that others can look at, then I would love to hear about it.
One thing I did notice is that in afterhours I was seeing 1200 shares selling at $10.88. Once that volume was sold then another 1200 shares came up for $10.88 again. I noticed this happening several times this evening.
POZN Buy/Sell Volume: 67,566/129,410
12,768 is left as not being sure of it being Sold on the Bid, or Buying on the Ask price.
Still hoping that by end of week or next week we could be at $10.
I am not sure if Good Friday is a trading day or not.
SNSS (.7988) stop loss executed at .77 this morning. Set stop loss at 20%. Just did not expect it to happen within 1 day if it was to happen. Why did I not set it at .75? Oh well, can not win them all. GLTA
POZN, my feeling is that before we push into the $10 range, I think we are going to see a pull back to around $9 first. I have been known to be wrong many of times, but just my feeling on how this will go this week.
SNSS, all in at .97
Hoping for good things to come this week.
POZN, with the run up lately, following another small push up today early and then dipped and flattened out for several hours, I am expecting that we may see this dip some more on what may have been profit taking in the flatness in my opinion. If it had run up and then flattened then I would feel more accumulation was occurring.
With the end of March coming I am almost expecting we may see a lil more of a dip coming. I hope not, but would not be surprised.
DARA and Reverse Splits.
I have seen Reserve Splits on different stocks open differently and trade that way. One stock had opened near it's prior day close, at double value though due to the RS, and went up through the day. Another stock I had seen opened lower and stayed flat or traded slighly lower all day.
BNVI, if I am understanding #2 and they are looking at increasing the number of Common Shares in the company from 190M to 350M; which I believe have been increased each year over the last 5 years; and the company's worth has not changed, are they not actually decreasing the pps for each common share stock?
Please help correct me if I am misunderstanding this. Thanks!
Message in reply to:
BNVI news- lloks like there's a plan to get the PPS over a buck if the menerbra news doesn't do it on its own
April [—], 2010
Dear Stockholder:
You are cordially invited to attend the Annual Meeting of Stockholders of Bionovo, Inc, a Delaware corporation (“Bionovo” or the “Company”). The meeting will be held on Monday, May 3, 2010, at 11:00 a.m. local time at the Company’s headquarters, located at 5858 Horton Street, Suite 400, Emeryville, California for the following purposes:
1. To elect five directors to the Board of Directors to hold office for a one-year term (the “Election of Directors”);
2. To approve an amendment to the Certificate of Incorporation, as amended, to increase the authorized shares of common stock from 190,000,000 shares to 350,000,000 shares, par value $0.0001 (the “Authorized Share Increase”);
3. To approve an amendment to the Certificate of Incorporation, as amended, to effect a reverse stock split of our common stock at a ratio to be determined by the Board of Directors within a range of between 1-for-[ ] and 1-for-[ ], with a corresponding reduction in the number of authorized shares of our common stock (the “Reverse Stock Split”), and to authorize the Board of Directors, in its discretion, to implement the Reverse Stock Split at an exchange ratio within this range and to do so at any time prior to our 2011 annual meeting of stockholders by filing an amendment to the Certificate of Incorporation.
4. To ratify the appointment of PMB Helin Donovan, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2010 (the “Ratification of Public Accountants”).
5. To conduct any other business properly brought before the meeting.
These items of business are more fully described in the Proxy Statement accompanying this Notice.
Only stockholders of record at the close of business on March 31, 2010 are entitled to notice of, and to vote at, the annual meeting or any adjournments or postponements thereof.
If you are a stockholder of record, you will find enclosed a proxy card or cards and an envelope in which to return the card(s). Your vote is important. Whether or not you plan to attend the annual meeting, I urge you to take a moment to vote on the items in this year’s proxy statement. Voting takes only a few minutes, and it will ensure that your shares are represented at the meeting.
I look forward to seeing you at the annual meeting, where you will hear about our results for 2009 and our priorities for 2010.
becker800, here is the link that was posted earlier.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48179550
Seeing a limit raised only $3 made me nervous on how this may play out.
It is already up over %50 in less than 1 month without any adjustments, i believe 1/3+ of that rise in the last two days, so in all it made me real nervous on what may happen.
I was not able to buy into this due to the pps, but will keep looking for new ones laying low, and watching this board also on more to come.
I do wish good luck to all into this stock, as well as all the ones you are in.
Grahamber, Maybe you want to take some profit tonight and hold the rest for tomorrow morning. That way you could at least be sure to take some now.
I am not sure how much more this will go higher. From the posting I saw earlier today, the limit was moved from $33 to $36 by one analyst. I can only take into account that he was looking at an approval, and with it being at the max now pretty much, I am not sure where it may go. Hopefully someone has some better idea than I what the max may be here. I am just going from the anaylst call earlier today.
pokertime1, about BestPicksEver, I see their timestamp on the .88 and bounce call to be 3 hours later then when it happened. Am I overlooking something other than hindsight on their call?
This is all I am seeing on their website about it:
APPA .. called at .88 for the bounce play hit high of $1.42 for our followers! Better then ANY Bank!
10:54 AM Mar 19th via web
bestpicksever
BestPicksEver
wallstarb, are you guys expecting it to maybe drop below the $1 mark?
Anyone notice shares available to short this morning?
I looked and can not find any available right off. Not sure how to take this. Maybe this stock is just too active to see any this morning after yesterday's trading volume.
I felt the same as you when they made that comment i refusing to take any type of questions.
I did not expect them to refuse questions after giving their statement. I don't think I have ever been on a call where the company refused to take any questions.
Good luck to all that either are holding or looking at buying in at this level.
MrRawlins, are you doing a PreMarket or regular order?
Doing as regular order will not be executed until 9:30 am at the earliest.
wallstarb, I have not seen you reference this from the news report found after the Clinical section.
Some of the FDA’s points were addressed in recent NDA amendments by A.P. Pharma that the Agency did not review prior to issuing the Complete Response Letter. The Company believes that these amendments may address some of the issues raised in the Complete Response Letter. The FDA has indicated that A.P. Pharma may incorporate applicable sections of these amendments by specific reference in its resubmission. The Company will be contacting the FDA to request an End-of-Review meeting to discuss the Complete Response Letter. A.P. Pharma is committed to expeditiously resolving the remaining issues required for FDA approval; however, based on the anticipated time needed to prepare a resubmission, the Company does not anticipate the commercial launch of APF530 in 2010.
I think we will find out more in the news conference and anything before then is purely speculative to what has all transpired and what was discussed with the FDA and AP Pharma.
Conference Call and Webcast Details
A.P. Pharma’s management will host a conference call on Friday, March 19, 2010 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) and interested investors may participate in the conference call by dialing (888) 732-6202 (domestic) or (719) 457-1017 (international) and use passcode 844199. In addition, the live conference call is being webcast and can be accessed on the "Calendar of Events" page of the "News & Events" section of the Company's website at http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.appharma.com&esheet=6220527&lan=en_US&anchor=www.appharma.com&index=1&md5=a3b8646b1d5d36cb28e0cea5cf959d48. A replay of the webcast will be available approximately two hours after the call and will be available through April 2, 2010.
mo282, what is odd is how one News Reporting company will say it is "Denies Approval", and another News Reporting company is saying it at "Sets Aside Approval".
Even among the news agencies they seem to have their own slant on how they read the report, or how they want it to be reported to the public.
Reuters Headline: FDA denies approval of AP Pharma nausea drug
DJ Realtimes News Headline: FDA Sets Aside Approval Of AP Pharma's Lead Drug For Now APPA
wallstarb, I think we will have a better idea of what may happen with this drug and company when we listen to the conference call at 9 am ET. Right now we are all just speculating on how this company is looking at the future and how the FDA responded to them if any phone discussions took place.
What I am trying to say, I think it would be prudent to at least listen to the conference call to see how it goes before ruling this company out completely.
FDA Sets Aside Approval Of AP Pharma's Lead Drug For Now APPA 03/19 07:35 AM
DOW JONES NEWSWIRES
AP Pharma Inc. (APPA:$2.06,00$0.50,0032.05%) said U.S. regulators need more answers about the company's lead drug candidate, a treatment for chemotheraphy-induced nausea, before they can approve the company's new-drug application.
The Food and Drug Administration said it has some worries about the dosing system, manufacturing of and data about APF530, which would be the second drug on the market for chemotherapy-induced nausea and vomiting if approved. Shares plunged 63% to 76 cents on the news. The stock had doubled the past three months.
AP Pharma (APPA:$2.06,00$0.50,0032.05%) has been waiting on FDA approval before pursuing partnership talks for marketing the drug in earnest. Although the company could market the drug on its own, Chief Executive Ronald Prentki had indicated the company was willing to wait for approval in order to get the best deal.
Friday, the company said the FDA was worried about the drug's two-syringe dosing system, including potential problems transferring material from one syringe to the other or the possible risk of improper administration.
The agency also identified deficiencies at some of AP Pharma's (APPA:$2.06,00$0.50,0032.05%) contract manufacturing facilities, which must be resolved. It wants the company to switch to a terminal sterilization process before approving the drug.
Although it didn't request any more clinical studies, the FDA wanted AP Pharma (APPA:$2.06,00$0.50,0032.05%) to review its existing late-stage trial data and reanalyze it. It requested the company do studies related to bioavailability, metabolism and heart arrhythmia, which AP Pharma (APPA:$2.06,00$0.50,0032.05%) said it expect won't take long. The agency also declined the company's request to waive a thorough QT study, which AP Pharma (APPA:$2.06,00$0.50,0032.05%) also said shouldn't take long.
The company had to cut more than a third of its work force last year and shelve several early-stage development programs to conserve cash, vesting a lot of its future success in APF530. The treatment would compete with Eisai Co.'s (ESALF:$39.3254,$0.0000,0.00%) ( 4523.TO, ESALY) Aloxi.
-By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@ dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/nae/al?rnd=T8y1viD%2BeszTXJbWSDhHaQ%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
03-19-100735ET
Copyright (c) 2010 Dow Jones & Company, Inc.
NVLT dropped from 1.67 to .30 just earlier this year at one moment.
Now trading in the low .20s.
I think that was a 82% drop.
A.P. Pharma Due off Extended-Hours Halt at 7:30 a.m. ET - Gets Response Letter from FDA on NDA, Agency Expresses Concerns, Details Other Issues 03/19 07:11 AM
07:11 AM Eastern Daylight Time, 03/19/2010 (MidnightTrader) -- A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting (CINV). APF530 is a long-acting formulation of granisetron utilizing the Company's proprietary Biochronomer drug delivery system.
The FDA expressed concerns relating to A.P. Pharma's two-syringe administration system. The agency identified certain deficiencies during inspections of the company's contract manufacturing facilities; it requested the company change to terminal sterilization prior to approval; and requested clarification and revision of certain analytical specifications proposed in the company's NDA.
The FDA did not request additional clinical efficacy studies, although it did ask for the re-presentation and re-analysis of select existing Phase 3 clinical trial data. The FDA requested the company perform two studies relating to bioavailability and metabolism. A.P. Pharma believes these studies should be of short duration in normal volunteers. The FDA did not accept the company's request to waive the requirement for a thorough QT study. A.P. Pharma believes this study should be of short duration in normal volunteers. The company plans to discuss the design and timing of the study with the FDA.
Price: 2.06, Change: 0, Percent Change: 0
http://www.midnighttrader.com
I have yet to read the news. I wanted to get what I saw posted here as soon as possible so everyone can read what I just saw posted.
We may also have to wait and see what they say in the conference call this morning.
Various Headline News on AP Pharma only.
Here are headline news from the DJ Realtime News with no additional information gived yet and with news pending to come out on them.
AP Pharma: FDA Expresses Concerns About Two-Syringe Admin System 03/19 07:01 AM
AP Pharma: FDA Requests Change To Terminal Sterilization>APPA 03/19 07:02 AM
AP Pharma: FDA Finds Some Deficiencies At Manufacturing Plants 03/19 07:02 AM
AP Pharma: No Request For Additional Clinical Efficacy Studies 03/19 07:03 AM
AP Pharma: FDA Seeks 2 Studies On Bioavailability, Metabolism 03/19 07:04 AM
AP Pharma: FDA Doesn't Waive Thorough QT Study >APPA 03/19 07:05 AM
AP Pharma: Studies Should Be Of Short Duration >APPA 03/19 07:05 AM
AP Pharma Doesn't See Commercial Launch Of APF530 In 2010 03/19 07:06 AM
AP Pharma, FDA To Discuss Design, Timing Of QT Study >APPA 03/19 07:06 AM
A.P. Pharma Receives FDA Complete Response Letter for APF530
(from Fidelity site)
A.P. Pharma Receives FDA Complete Response Letter for APF530
- Company to host conference call at 9:00 a.m. ET on Friday, March 19, 2010 - 03/19 07:00 AM
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- A.P. Pharma, Inc. (APPA:$2.06,00$0.50,0032.05%) , a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting (CINV). APF530 is a long-acting formulation of granisetron utilizing the Company’s proprietary Biochronomer™ drug delivery system. A conference call has been scheduled for Friday, March 19, 2010 at 9:00 a.m. Eastern Time.
A Complete Response Letter is issued by the FDA'sCenter for Drug Evaluation and Research when the review of a file is completed and questions remain that preclude the approval of the NDA in its current form. The primary points raised in the FDA Complete Response Letter are discussed below:
Dosing System
The FDA expressed concerns relating to A.P. Pharma’s two-syringe administration system, including potential issues with the transfer of material from one syringe to the other syringe prior to patient administration, certain components used in the dosing system and the potential risk of improper administration of the drug product.
Chemistry, Manufacturing and Control
The FDA has completed inspections of A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) and several of its contract manufacturing facilities. The Agency identified certain deficiencies during these inspections, and satisfactory resolution of these deficiencies will be required for approval.
During the NDA review, the FDA asked that the Company determine if terminal sterilization with gamma irradiation is a feasible approach to enhance the assurance of sterility. A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) has subsequently demonstrated that terminal sterilization is feasible, and the FDA has requested the Company change to terminal sterilization prior to approval.
The FDA requested clarification and revision of certain analytical specifications proposed in the Company’s NDA.
Clinical
The FDA did not request additional clinical efficacy studies, although the Agency has asked for the re-presentation and re-analysis of select existing Phase 3 clinical trial data.
The FDA requested the Company perform two studies relating to bioavailability and metabolism. A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) believes these studies should be of short duration in normal volunteers.
The FDA did not accept the Company’s request to waive the requirement for a thorough QT study. A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) believes this study should be of short duration in normal volunteers. The Company plans to discuss the design and timing of the study with the FDA.
Some of the FDA’s points were addressed in recent NDA amendments by A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) that the Agency did not review prior to issuing the Complete Response Letter. The Company believes that these amendments may address some of the issues raised in the Complete Response Letter. The FDA has indicated that A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) may incorporate applicable sections of these amendments by specific reference in its resubmission. The Company will be contacting the FDA to request an End-of-Review meeting to discuss the Complete Response Letter. A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) is committed to expeditiously resolving the remaining issues required for FDA approval; however, based on the anticipated time needed to prepare a resubmission, the Company does not anticipate the commercial launch of APF530 in 2010.
Conference Call and Webcast Details
A.P. Pharma’s management will host a conference call on Friday, March 19, 2010 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) and interested investors may participate in the conference call by dialing (888) 732-6202 (domestic) or (719) 457-1017 (international) and use passcode 844199. In addition, the live conference call is being webcast and can be accessed on the "Calendar of Events" page of the "News & Events" section of the Company's website at www.appharma.com. A replay of the webcast will be available approximately two hours after the call and will be available through April 2, 2010.
About APF530
A.P. Pharma's (APPA:$2.06,00$0.50,0032.05%) lead product candidate, APF530, is being developed for the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting (CINV). APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company’s proprietary Biochronomer™ drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Injections and oral tablets containing granisetron are approved for the prevention of acute onset CINV, but not for delayed onset CINV. Granisetron was selected because it is widely prescribed by physicians based on a well-established record of safety and efficacy. In September 2008, A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) reported positive top-line results from its pivotal Phase 3 study. In this multi-center, randomized trial that enrolled 1,395 cancer patients, APF530 was shown to be equally as effective as (statistically non-inferior to) palonosetron (Aloxi®) in the prevention of both acute onset and delayed onset CINV. Palonosetron is the only injectable 5-HT3antagonist FDA-approved for the prevention of delayed onset CINV. APF530 was also generally well-tolerated in this study. A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) received a Complete Response Letter on the APF530 NDA in March 2010 and intends to respond to the issues in the Complete Response Letter in as timely and expeditious a manner as possible.
About CINV
Prevention and control of nausea and vomiting, or emesis, are very important in the treatment of cancer patients. The majority of patients receiving chemotherapy will experience some degree of emesis if not prevented with an anti-emetic, typically administered just prior to chemotherapy.
Chemotherapy treatments can be classified as moderately emetogenic, meaning that 30% to 90% of patients experience CINV, or highly emetogenic, meaning that more than 90% of patients experience CINV, if they do not receive an anti-emetic. Acute onset CINV occurs within the first 24 hours following chemotherapy treatment. Delayed onset CINV occurs more than 24 hours after treatment and may persist for several days. Prevention of CINV is important because the distress caused by CINV can severely disrupt patient quality of life and can lead some patients to delay or discontinue chemotherapy.
About A.P. Pharma (APPA:$2.06,00$0.50,0032.05%)
A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company’s primary focus is on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). A.P. Pharma (APPA:$2.06,00$0.50,0032.05%) received a Complete Response Letter on the APF530 NDA in March 2010 and is in the process of preparing a resubmission responsive to the deficiencies listed in the Complete Response Letter. The Company has additional clinical and preclinical stage programs in the area of pain management, all of which utilize its bioerodible injectable and implantable delivery systems. For further information, visit the Company's web site at www.appharma.com.
A.P. Pharma’s Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including uncertainties associated with timely development, approval, launch and acceptance of new products, satisfactory completion of clinical studies, establishment of new corporate alliances, progress in research and development programs and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law.
Source: A.P. Pharma, Inc. (APPA:$2.06,00$0.50,0032.05%)
Checked for news, nothing reported yet.
Not even the company has anything posted.
Not sure if I have seen this before with trading halted at just after 4 PM saying news is pending, and then over 12 hours later nothing is being reported.
Just checking and no news yet. Makes me wonder on why they would not post the FDA Letter since it was halted around 4:18 PM.